New York State Common Retirement Fund Buys 370,498 Shares of Enfusion, Inc. (NYSE:ENFN)

New York State Common Retirement Fund raised its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 23.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,926,968 shares of the company’s stock after purchasing an additional 370,498 shares during the quarter. New York State Common Retirement Fund’s holdings in Enfusion were worth $19,848,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in ENFN. Harbor Capital Advisors Inc. raised its stake in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Belvedere Trading LLC acquired a new position in shares of Enfusion in the 3rd quarter valued at $114,000. Paloma Partners Management Co bought a new position in shares of Enfusion during the 3rd quarter worth about $157,000. Centiva Capital LP lifted its holdings in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares during the period. Finally, Azora Capital LP boosted its position in shares of Enfusion by 6.8% during the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after acquiring an additional 1,890 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

Insider Buying and Selling

In other Enfusion news, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now owns 526,702 shares of the company’s stock, valued at $5,335,491.26. This represents a 0.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the completion of the transaction, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 57,367 shares of company stock worth $591,335 in the last three months. Insiders own 36.44% of the company’s stock.

Enfusion Trading Up 1.3 %

Shares of Enfusion stock opened at $11.50 on Friday. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80. The firm’s 50-day moving average price is $10.82 and its two-hundred day moving average price is $9.66. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 287.45, a P/E/G ratio of 1.85 and a beta of 0.96.

Analyst Ratings Changes

ENFN has been the subject of a number of analyst reports. Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.50.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.